ST Yinfu: Subsidiary's Nalbuphine Hydrochloride Injection Added New Indication Drug Registration Approval Application Accepted.

ST Renfu Announcement: Recently, Renfu Pharmaceutical Co., Ltd., a holding subsidiary of the Company, has received the "Acceptance Notice" of the drug registration and listing license application for Nalbuphine Hydrochloride Injection issued by the National Medical Products Administration. The Nalbuphine Hydrochloride Injection was approved for marketing in 2013, and its current indications include "as an analgesic used for anesthesia induction during complex anesthesia, and postoperative analgesia." In September 2022, Renfu obtained the clinical trial approval notice for the use of the chemical drug class 2.4 for analgesia in patients in intensive care units. As of now, the cumulative research and development investment in this project is approximately 16 million RMB.